Mental health respite facilities are filling care gaps in over a dozen states

The FDA hit Citius Phar­ma­ceu­ti­cals with a com­plete re­sponse let­ter (CRL) for its treat­ment of re­lapsed or re­frac­to­ry cu­ta­neous T-cell lym­phoma (CT­CL), a rare form

Prime Med­i­cine is con­sid­er­ing de­vel­op­ing cell ther­a­pies for au­toim­mune dis­eases and will like­ly look for a part­ner for can­cer cell ther­a­pies, CEO Kei­th Gottes­di­ener said dur­ing